Compare Cardinal Health Inc (CAH) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs iShares China Large-Cap ETF — how do they compare? Cardinal Health Inc trades at $236.95 (market cap $55.88B), while iShares China Large-Cap ETF trades at $35.29. The key difference: Cardinal Health Inc pays a 0.86% dividend while iShares China Large-Cap ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| CAH | FXI | |
|---|---|---|
Market Cap | $55.88B | — |
Sector | Health | — |
52-Week High | $240.26 | $41.75 |
52-Week Low | $146.04 | $31.59 |
Enterprise Value | $59.91B | — |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
FXI, the iShares China Large-Cap ETF, trades at $35.26, down 3.37% on the day, reflecting recent pressure on Chinese equities. Technical indicators show a bullish moving average signal but neutral oscillators, with key resistance at $37. Recent news highlights China's export strength and state-backed economic support, though geopolitical tensions and U.S. restrictions pose headwinds. The ETF offers exposure to China's financial and industrial giants, with a dividend scheduled for June 2026.
The outlook for FXI is mixed; bullish technical trends and China's policy support may drive gains, but risks include U.S.-China tensions and domestic economic volatility. Investors should weigh diversification benefits against regulatory and macroeconomic uncertainties, with Wall Street sentiment cautious amid fluctuating analyst views.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
